Afuco™ Anti-Human KLRC1 ADCC Recombinant Antibody (IPH 2201), ADCC Enhanced (CAT#: AFC-453CL)

Anti-KLRC1 ADCC Enhanced Antibody (IPH 2201) is an ADCC enhanced antibody produced by our Afuco™ platform. IPH2201 is a first-in-class humanized IgG4 targeting NKG2A receptors expressed on tumor infiltrating cytotoxic NK and CD8 T lymphocytes. IPH2201 may re-establish a broad anti-tumor response mediated by NK and T cells. IPH2201 may also enhance the cytotoxic potential of other therapeutic antibodies. IPH2201 is currently in Phase II development in various cancer indications and combinations.

Specific Inquiry
  • Size:

  • Conjugation:

  • Endotoxin:

  • Purity:

  • Formats:

  • Isotype Switching:

  • Fc Engineering:

  • Modalities:

Custom Production

We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.

Sequences:
Isotype :
Purity :
Endotoxin :
Quantity :
Conjugation :
Fc Engineering :
Modalities :
Other Requirements:
We require custom production
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Subcellular Location
RNA Expression

Specifications

  • Host Species
  • Humanized
  • Derivation
  • Humanized
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Related Disease
  • Autoimmune Diseases; Inflammatory Diseases; Rheumatoid Arthritis

Product Property

  • Purity
  • >95% by HPLC
  • Storage
  • Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • KLRC1; killer cell lectin-like receptor subfamily C, member 1; NKG2; NKG2A; CD159A; NKG2-A/NKG2-B type II integral membrane protein; NK cell receptor A; C-lectin type II protein; natural killer cell lectin; natural killer group protein 2; NKG2-1/B activating NK receptor; NKG2-A/B-activating NK receptor; CD159 antigen-like family member A; NKG2-A/B type II integral membrane protein

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "KLRC1"

Select a product category from the dropdown menu below to view related products.
Please select product type
IgG Antibodies Fab Antibodies ScFv Antibodies Humanized Antibodies ADCC Enhanced Antibodies ScFv-Fc Chimeras Extracellular Vesicle Antibodies

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for AFC-453CL. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to compare

Go to compare